Immunoregulation during toxoplasmosis

Chemical Immunology

Volumn 70, Issue , 1998, Pages 81-102

  Alexander, James ^a   Hunter, Christopher A ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOXOPLASMA GONDII VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; BRAIN INFECTION; CELLULAR IMMUNODEFICIENCY; DISEASE SEVERITY; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION CONTROL; MICROGLIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINE PRODUCTION; VIRULENCE;

EID: 0031964559     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058701     Document Type: Review

References (145)

1. Jackson MH, Hutchison WM: The prevalence and source of Toxoplasma infection in the environment. Adv Parasitol 1989;28:55-105.
2. Sibley LD, Howe DK: Genetic basis of pathogenicity in toxoplasmosis. Curr Top Microbiol Immunol 1996;219:3-16.
3. Darde ML: Biodiversity in Toxaplasma gondii. Curr Top Microbiol Immunol 1996;219:27-41.
4. Luft BJ, Remington JS: Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-222.
5. Ambroise-Thomas P, Pelloux H: Toxoplasmosis - Congenital and in immuno-compromised patients: A parallel. Parasitol Today 1993;9:61-62.
6. Sibley LD, Boothroyd JC: Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 1992;350:82-85.
7. Howe DK, Sibley LD: Toxoplasma gondii is comprised of 3 clonal lineages: Correlation of parasite genotype with human disease. J Infect Dis 1995;13:322-356.
8. Rinder H, Thomschkle A, Darde ML, Loscher T: Specific DNA polymorphisms discriminate between virulence and non-virulence to mice in nine Toxoplasma gondii isolates. Mol Biochem Parasitol 1995;69:123-126.
9. Araujo FG, Williams DM, Grumet FC, Remington JS: Strain dependent differences in murine susceptibility to Toxoplasma gondii. Infect Immun 1976;13:1528-1530.
10. Blackwell JM, Roberts CW, Alexander J: Influence of genes within the MHC on mortality and brain cyst development in mice infected with Toxoplasma gondii: Kinetics of immune regulation in BALB H-2 congenic mice. Parasit Immunol 1993;15:317-324.
11. Brown CR, McLeod R: Mechanisms of survival of mice during acute and chronic Toxoplasma gondii infection. Parasitol Today 1994;10:290-292.
12. Denkers EY, Caspar P, Sher A: Toxoplasma gondii possesses a super antigen that selectively expands murine T cell receptor Vβ5-bearing CD8+ lymphocytes. J Exp Med 1994;180:985-994.
13. Denkers EY, Caspar P, Hieny S, Sher A: Toxoplasma gondii infection induces specific nonresponsiveness in lymphocytes bearing the Vβ5 chain of the mouse T cell receptor. J Immunol 1996;156: 1089-1094.
14. Denkers EY: A Toxoplasma gondii superantigen. Biological effects and implications for the host-parasite interaction. Parasitol Today 1996;12:362-366.
15. McLeod R, Johnson J, Estes R, Mack D: Immunogenetics in pathogenesis and protection against toxoplasmosis. Curr Top Microbiol Immunol 1996;219:95-112.
16. McLeod R, Skamene E, Brown CR, Eisenhauer PB, Mack DG: Genetic regulation of early survival and cyst number after peroral Toxoplasma gondii infection of A×B/B×A recombinant inbred and B10 congenic mice. J Immunol 1989;143:3031-3034.
17. Brown CR, Hunter CA, Estes RG, Beckmann J, Forman J, David C, Remington JS, McLeod R: Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology 1995;85:419-428.
18. Hunter CA, Litton MJ, Remington JS, Abrams JS: Immunocytochemical detection of cytokines in the lymph nodes and brains of mice resistant or susceptible to toxoplasmic encephalitis. J Infect Dis 1994;170:939-945.
19. Suzuki Y, Wong SY, Grumet FC, Fessel J, Montoya JG, Zolopa AR, Patmore A, Schumacher-Perdreau F, Schrappe M, Koppen S, Ruf B, Brown BW, Remington JS: Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis 1996;173: 265-268.
20. Blackwell JM, Roberts CW, Roach TI, Alexander J: Influence of macrophage resistance gene Lsh/ Ity/Bcg (candidate) NRamp on Toxoplasma gondii infection in mice. Clin Exp Immunol 1994;97: 107-112.
21. Deckert-Schluter M, Schluter D, Schmidt D, Schwendmann G, Wiestler OD, Hof H: Toxoplasma encephalitis in congenic B10 and BALB mice: Impact of genetic factors on the immune response. Infect Immun 1994;62:221-228.
22. Deckert-Schluter M, Albrecht S, Hof H, Wiestler OD, Schluter D: Dynamics of the intracerebral and splenic cytokine mRNA production in Toxoplasma gondii-resistant and -susceptible congenic strains of mice. Immunology 1995;85:408-418.
23. Roberts CW, Satoskar A, Alexander J: The influence of sex steroids and pregnancy associated hormones on the development and maintenance of immunity to parasite infection. Parasitol Today 1996:12:382-388.
24. Goyal M, Ganguly NK, Mahajan RC: Natural killer cell cytotoxicity against Toxoplasma gondii in acute and chronic toxoplasmosis. Med Sci Res 1988;16:375-377.
25. Hauser WE, Sharma SD, Remington JS: Natural killer cells induced by acute and chronic Toxoplasma infection. Cell Immunol 1982;69:330-346.
26. Subauste CS, Dawson L, Remington JS: Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii. J Exp Med 1992;176:1511-1519.
27. Hunter CA, Subauste CS, Van Cleave VH, Remington JS: Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: Regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun 1994;62:2818-2824.
28. Suzuki Y, Orelana MA, Schreiber RD, Remington JS: Interferon-γ: The major mediator of resistance against Toxoplasma gondii. Science 1988;240:516-518.
29. Sibley LD, Adams LB, Fukutomi Y, Krahenbuhl JL: Tumor necrosis factor-α triggers antitoxoplasmal activity of IFN-γ primed macrophages. J Immunol 1991;147:2340-2345.
30. Pfefferkorn ER, Eckel M, Rebhun S: Interferon-γ suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan. Mol Biochem Parasitol 1986;20:215-224.
31. Daubener W, Remscheid C, Nockemann S, Pilz K, Seghrouchini S, Mackenzie C, Hadding U: Antiparasite effector mechanism in human brain tumor cells: Role of interferon-γ and tumor necrosis factor-α. Eur J Immunol 1996;26:487-492.
32. Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-531.
33. Johnson LL: SCID mouse models of acute and relapsing chronic Toxoplasma gondii infections. Infect Immun 1992;60:3719-3724.
34. Hunter CA, Abrams JS, Beaman MH, Remington JS: Cytokine mRNA in the central nervous system of SCID mice infected with Toxoplasma gondii: Importance of T-cell-independent regulation of resistance to T. gondii. Infect Immun 1993;61:4038-4044.
35. Schluter D, Deckert-Schluter M, Schwendemann G, Brunner H, Hof H: Expression of major histocompatability complex class II antigens and levels of interferon-γ, tumor necrosis factor, and interleukin-6 in cerebrospinal fluid and serum in Toxoplasma gondii-infected SCID and immunocompetent C.B-17 mice. Immunology 1993;78:430-435.
36. Sher A, Oswald IP, Hieny S, Gazzinelli R: Toxoplasma gondii induces a T-independent IFN-γ response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-α. J Immunol 1993;150:3982-3989.
37. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A: Interleukin-12 is required for the T-lymphocyte-independent induction of interferon-γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 1993;90:6115-6119.
38. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A: Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 1994;153:2533-2543.
39. Hauser WE, Sharma SD, Remington JS: Augmentation of NK cell activity by soluble and particulate fractions of Toxoplasma gondii. J Immunol 1983;131:458-463.
40. Sharma SD, Verhoef J, Remington JS: Enhancement of human natural killer cell activity by subcellular components of Toxoplasma gondii. Cell Immunol 1986;86:317-326.
41. Grunvald E, Chiaramonte M, Hieny S, Wysocka M, Trinchieri G, Vogel S, Gazzinelli R, Sher A: Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii. Infect Immun 1996;64:2010-2018.
42. Hunter CA, Chizzonite R, Remington JS: Interleukin-1β is required for the ability of IL-12 to induce production of IFN-γ by NK cells: A role for IL-1β in the T cell independent mechanism of resistance against intracellular pathogens. J Immunol 1995;155:4347-4354.
43. Hunter CA, Ellis-Neyer L, Gabriel K, Kennedy M, Linsley P, Remington JS: The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol 1997;158:2285-2293.
44. Hunter CA, Bermudez L, Beernink H, Waegell W, Remington JS: Transforming growth factor-β inhibits interleukin-12-induced production of interferon-γ by natural killer cells: A role for transforming growth factor-β in the regulation of T-cell independent resistance to Toxoplasma gondii. Eur J Immunol 1995;25:994-1000.
45. Bellonc G, Aste-Amezaga M, Trinchieri G, Rodeck U: Regulation of NK cell functions by TGF-β1. J Immunol 1995;155:1066-1073.
46. Tripp CS, Wolf SF, Unanue ER: Interleukin-12 and tumor necrosis factor-α are costimulators of interferon-γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis. and interleukin-10 is a physiological antagonist. Proc Natl Acad Sci USA 1993;90:3725-3729.
47. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin-10 inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
48. Rennick D, Berg D, Holland G: Interleukin-10: An overview. Prog Growth Factor Res 1992;4: 207-227.
49. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;146:3815-3822.
50. Hsieh CS, Macatonia SE, Tripp CS, Wolf S, O'Garra A, Murphy KM: Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
51. Scott P: IL-12: Initiation cytokine for cell-mediated immunity. Science 1993;260:496-497.
52. Gajewski TF, Fitch FW: Differential activation of murine Th1 and Th2 clones. Res Immunol 1991; 142:19-23.
53. Denkers EY, Sher A, Gazzinelli RT: T cell interactions with Toxoplasma gondii: Implications for processing of antigen for class I-restricted recognition. Res Immunol 1993;14:51-57.
54. Khan IA, Kasper LH: IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. J Immunol 1996;157:2103-2108.
55. Croft M, Carter L, Swain SL, Dutton RW: Generation of polarised antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994;180:1715-1728.
56. Brown CR, McLeod R: Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol 1990;145:3438-3441.
57. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A: Synergistic role of CD4+ and CD8+ lymphocytes in IFN-γ production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 1991;146:286-292.
58. Khan IA, Ely KH, Kasper LH: A purified parasite antigen (P30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 1991;47:3501-3506.
59. Parker SJ, Roberts CW, Alexander J: CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 1991; 84:207-212.
60. Subuaste CS, Koniaris AH, Remington JS: Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells. J Immunol 1991;147:3955-3959.
61. Gazzinelli RT, Denkers EY, Sher A: Host resistance to Toxoplasma gondii: Model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect Agents Dis 1993;2:139-149.
62. Yano A, Aosai F, Ohta M, Hasekura H, Sugana K, Hayashi S: Antigen presentation by Toxoplasma gondii-infected cells to CD4+ proliferative T cells and CD8+ cytotoxic cells. J Parasitol 1989;75: 411-416.
63. Khan IA, Smith KA, Kasper LH: Induction of antigen-specific parasiticidal cytotoxic T cell splenocytes by a major membrane protein (p30) of Toxoplasma gondii. J Immunol 1988;141:3600-3605.
64. Curiel TJ, Krug EC, Purner MB, Poignard P, Berens RL: Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J Immunol 1993; 151:2024-2031.
65. Denkers EY, Scharton Kersten T, Barbieri S, Caspar P, Sher A: A role for CD4+NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J Exp Med 1996;184:131-139.
66. Denkers EY, Gazzinelli RT, Martin D, Sher A: Emergence of NK1.1+ cells as effectors of immunity to Toxoplasma gondii in MHC class I-deficient mice. J Exp Med 1993;178:1465-1472.
67. Araujo FS: Depletion of L3T4+ (CD+) T lymphocytes prevent the development of resistance to Toxoplasma gondii in mice. Infect Immun 1991;59:1614-1619.
68. Vollmer TL, Waldour MK, Steinman L, Conley FK: Depletion of T-4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: A model of superinfection in AIDS. J Immunol 1987;138:3737-3741.
69. Remington JS: Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis. J Immunol 1989;142:954-958.
70. Liesenfeld O, Kosek J, Remington JS, Suzuki Y: Mice definition in α/β CD4 T cells did not develop necrosis in the ilea but mice deficient in γ/δ or CD8+ T cells did. J Exp Med 1996;184:597-607.
71. Chardes T, Buzoni-Gatel D, Lepage A, Bernard F, Bout D: Toxoplasma gondii oral infection induces specific cytotoxic CD8α/α Thy-1+ gut intraepithelial lymphocytes, lytic for parasite-infected enterocytes. J Immunol 1994;153:4596-4603.
72. Chardes T, Velge-Roussel F, Mevelec P, Mevelec M-N, Buzoni-Gatei D, Bout D: Mucosal and systemic cellular immune responses induced by Toxoplasma gondii antigens in cyst orally infected mice. Immunology 1993;78:421-429.
73. Hisaeda H, Nagasawa H, Maeda K, Maekawa Y, Ishikawa H, Ito Y, Good RA, Himeno K: γδ T cells play an important role in hsp65 expression and in acquiring protective immune responses against infection with Toxoplasma gondii. J Immunol 1995;154:244-251.
74. Langermans JAM, Van der Hulst MEB, Nibbering PH, Hiemstra PS, Fransen L, Van Furth R: IFN-γ induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-α. J Immunol 1992;148:568-574.
75. Bohne W, Heesemann J, Gross U: Induction of bradyzoite-specific Toxoplasma gondii antigens in gamma interferon-treated mouse macrophages. Infect Immun 1993;61:1141 1145.
76. McCabe RE, Luft BJ, Remington JS: Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis 1984;150:961-962.
77. Bohne W, Heesemann J, Gross U: Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite specific antigens: A possible role for nitric oxide in triggering stage conversion. Infect Immun 1994;62:1761-1767.
78. Weiss LM, Laplace D, Takvorian PM, Tanowitz HP, Cali A, Wittner M: A cell culture system for study of the development of Toxoplasma gondii bradyzoites. J Eukaryot Microbiol 1995;42:150-157.
79. Khan IA, Matsuura T, Fonseka S, Kasper LH: Production of nitric oxide is not essential for protection against acute Toxoplasma gondii infection in IRF-1 -/-mice. J Immunol 1996;156: 636-646.
80. Yong EC, Chi EY, Fritsche TR, Henderson WR: Human platelet-mediated cytotoxicity against Toxoplasma gondii: Role of thromboxane. J Exp Med 1991;173:65-78.
81. Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, Kasper LH: Antibodies to Toxoplasma gondii major surface protein (SAG1 P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. J Immunol 1993;150:3951-3964.
82. Jones TC, Len L, Hirsch JG: Assessment in vitro of immunity against Toxoplasma gondii. J Exp Med 1975;141:466-482.
83. Luft BJ, Remington JS: Toxoplasmic encephalitis. J Infect Dis 1988;157:1-6.
84. Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, Bourland DD, Uttamchandani R, Fuhrer J, Jacobson J, Morlat P, Vilde JL, Remington JS: Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993;329:995-1000.
85. Cserr HF, Knopf PM: Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol Today 1993;13:507-510.
86. Benveniste EN: Lymphokine and monokines in the neuroendocrine system. Prog Allergy 1988;43: 84-120.
87. Fontana A, Frei K, Bodmer S, Hofer E: Immune-mediated encephalitis: On the role of antigen-presenting cells in brain tissue. Immunol Rev 1987;100:185-201.
88. Fabry Z, Raine CS, Hart MN: Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. J Immunol 1994;15:218-224.
89. Werkle H: Lymphocyte traffic to the brain; in Partridge WM (ed): The Blood Brain Barrier. New York, Raven Press, 1993, pp 67-85.
90. Israelski DM, Remington JS: AIDS associated toxoplasmosis; in Sande MA, Volderding PA (eds): The Medical Management of AIDS, ed 3. Philadelphia, Saunders, 1992, pp 319-345.
91. Clerici M, Shearer GM: A Th1-Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
92. Gazzinelli RT, Bala S, Stevens R, Baseler M, Wahl L, Kovacs J, Sher A: HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J Immunol 1995;155:1565-1574.
93. Delemarre FGA, Stevenhagen A, Kroon FP, Van Eer MY, Meenhorst PL, Van Furth R: Effect of IFN-γ on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients. Immunology 1995;83:646-650.
94. 2. AIDS 1995;9:441-445.
95. Biggs B-A, Hewish M, Kent S, Hayes K, Crowe SM: HIV-1 infection of human macrophages impairs phagocytosis and killing of Toxoplasma gondii. J Immunol 1995;154:6132-6139.
96. Gazzinelli RT, Sher A, Cheever A, Gerstberger S, Martin M, Dickie P: Infection of human immuno-deficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo. J Exp Med 1996;183:1645-1655.
97. Hunter CA, Roberts CW, Murray M, Alexander J: Detection of cytokine mRNA in the brains of mice with toxoplasmic encephalitis. Parasite Immunol 1992;14:405-413.
98. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A: Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infections with Toxoplasma gondii. J Immunol 1992;149:175-180.
99. Suzuki Y, Remington JS: Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4 T cells in mice. J Immunol 1988;140:3943-3946.
100. Beaman MH, Araujo FG, Remington JS: Protective reconstitution of the SCID mouse against reactivation of Toxoplasmic encephalitis. J Infect Dis 1994;169:375-383.
101. Hunter CA, Roberts CW, Alexander J: Kinetics of cytokine mRNA production in the brains of mice with progressive toxoplasmic encephalitis. Eur J Immunol 1992;22:2317-2322.
102. Gazzinelli RT, Eltoum I, Wynn TA, Sher A: Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-α and correlates with the down-regulated express of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 1993;151:3672-3681.
103. Suzuki Y, Conley FK, Remington JS: Importance of endogenous IFN-γ for prevention of toxoplasmic encephalitis in mice. J Immunol 1989;143:2045-2050.
104. Suzuki Y, Conley FK, Remington JS: Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infect Immun 1990;58:3050-3055.
105. Hayashi S, Chan C-C, Gazzinelli R, Roberge FC: Contribution of nitric oxide to the host parasite equilibrium in toxoplasmosis. J Immunol 1996;156:1476-1481.
106. Suzuki Y, Yang Q, Conley FK, Abrams JS, Remington JS: Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun 1994;62:2773-2778.
107. Hunter CA, Remington JS: Immunopathogenesis of toxoplasmic encephalitis. J Infect Dis 1994; 170:1057-1067.
108. Roberts CW, Ferguson DJP, Jebbari J, Satoskar A, Bluethmann H, Alexander J: Different roles for interleukin-4 during the course of Toxoplasma gondii infection. Infect Immun 1996;64:897-904.
109. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A: In the absence of endogenous IL-10 mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. Immunol 1996;157:798-805.
110. Suzuki Y, Yang Q, Yang S, Nguyen N, Lim S, Liesenfeld O, Kojima T, Remington JS: IL-4 is protective against development of toxoplasmic encephalitis. J Immunol 1996;157:2564-2569.
111. Kamogawa Y, Minasi LE, Carding SR, Bottomly K, Flavell RA: The relationship of IL-4 and IFNγ-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993;75:985-995.
112. Ferguson DJP, Graham DI, Hutchison WM: Pathological changes in the brains of mice infected with Toxoplasma gondii: A histological, immunocytochemical, and ultrastructural study. Int J Exp Pathol 1991;72:463-474.
113. Chao CC, Hu S, Gekker G, Novick WJ, Remington JS, Peterson PK: Effects of cytokines on multiplication of Toxoplasma gondii in microglial cells. J Immunol 1993;150:3404-3410.
114. Peterson PK, Gekker G, Hu S, Chao C: Intracellular survival and multiplication of Toxoplasma gondii in astrocytes. J Infect Dis 1993;168:1472-1478.
115. Jun CD, Kim SH, Soh CT, Kang SS, Chung HT: Nitric oxide mediates the toxoplasmastatic activity of murine microglial cells in vitro. Immunol Invest 1993;22:487-501.
116. Peterson PK, Gekker G, Hu S, Chao CC: Human astrocytes inhibit intracellular multiplication of Toxoplasma gondii by a nitric oxide-mediated mechanism. J Infect Dis 1995;171:516-518.
117. Hunter CA, Suzuki Y, Subauste CS, Remington JS: Cells and cytokines in resistance to Toxoplasma gondii. Curr Top Microbiol Immunol 1996;219:113-125.
118. Black CM, Israelski DM, Suzuki Y, Remington J: Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi. Immunology 1990;68:570-574.
119. Alexander J, Jebbari H, Bluethmann H, Satoskar A, Roberts CW: Immunological control of Toxoplasma gondii and appropriate vaccine design. Curr Top Microbiol Immunol 1996;219:183-195.
120. Clark IA, Rockett KA, Cowden WB: Proposed link between cytokines, nitric oxide and human cerebral malaria. Parasitol Today 1991;7:205-207.
121. Ellis Neyer L, Grunig G, Fort M, Remington JS, Rennick D, Hunter CA: Role of interleukin-10 in regulation of T cell-dependent and T cell-independent mechanisms of resistance to Toxoplasma gondii. Infect Immun 1997;65:1675-1682.
122. Candolfi E, Hunter CA, Remington JS: Mitogen- and antigen-specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect Immun 1994;62:1995-2001.
123. Haque S, Khan I, Hague A, Kasper LH: Impairment of the cellular immune response in acute murine toxoplasmosis: Regulation of interleukin-2 production and macrophage-mediated inhibitory effects. Infect Immun 1994;62:2908-2916.
124. Khan IA, Matsuura T, Kasper LH: IL-10 mediates immunosuppression following acute infection with T. gondii in mice. Parasite Immunol 1995;17:185-195.
125. Sharma SD, Hofflin JM, Remington JS: In vivo recombinant IL-2 enhances survival against a lethal challenge with T. gondii. J Immunol 1985;135:4160-4163.
126. Kasper LH, Matsuura T, Khan IA: IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii. J Immunol 1995;155:4798-4804.
127. Roberts CW, Cruickshank SM, Alexander J: Sex-determined resistance to Toxoplasma gondii is associated with temporal differences in cytokine production. Infect Immun 1995;63:2549-2555.
128. Walker W, Roberts CW, Ferguson DJP, Jebbari H, Alexander J: Innate immunity to Toxoplasma gondii infection is gender-influenced and is associated with differences in interleukin-12 and interferon-γ production. Infect Immun 1997;65:1119-1121.
129. Buxton D: Toxoplasmosis: The first commercial vaccine. Parasitol Today 1993;9:335-337.
130. Dubey JP: Toxoplasmosis. J Am Vet Med Assoc 1994;205:1593-1598.
131. Dubey JP, Baker DG, Davis SW, Urban JD, Sken SK: Persistence of immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii. Am J Vet Res 1994;55:982-987.
132. Buxton D, Thomson K, Maley S, Wright S, Bos HJ: Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec 1991; 129:89-93.
133. Gallicha WS, Rosenthal KL: Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunity. J Exp Med 1996;184:1871-1879.
134. McLeod R, Skamene E, Brown CR, Eisenhauer PB, Gibori G: Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital Toxoplasma challenge. J Immunol 1988;140:1632-1637.
135. Debard N, Buzoni-Gatel D, Bout D: Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun 1996;64:2158-2166.
136. Fischer HG, Reichmann G, Hadding U: Toxoplasma proteins recognized by protective T lymphocytes. Curr Top Microbiol Immunol 1996;219:175-182.
137. Roberts CW, Brewer JM, Alexander J: Congenital toxoplasmosis in the Balb/c mouse: Prevention of vertical disease transmission and fetal death by vaccination. Vaccine 1994;12:1389-1394.
138. Kasper LH: Identification of stage specific antigens of Toxoplasma gondii. Infect Immun 1989;57: 668-672.
139. Zhang YW, Smith JE: Toxoplasma gondii: Reactivity of murine sera against tachyzoite and cyst antigens via FAST-ELISA. Int J Parasitol 1995;25:637-640.
140. Freyre A, Choromanski L, Fishback JL, Popiel I: Immunisation of cats with tissue cysts, bradyzoites, tachyzoites of the T-263 strain of Toxoplasma gondii. J Parasitol 1993;79:716-719.
141. Lunden A, Lovgren K, Uggla A, Araujo FG: Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes. Infect Immun 1993;61:2639-2643.
142. Bulow R, Boothroyd JC: Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J Immunol 1991;147:3496-3500.
143. Kasper LH, Currie KM, Bradley MS: An unexpected response to vaccination with a purified membrane tachyzoite antigen (P30) to Toxoplasma gondii. J Immunol 1985;134:3426-3431.
144. Lopes LM, Chain BM: Liposome mediated delivery stimulates a class I restricted cytotoxic T cell response to soluble antigen. Eur J Immunol 1992;22:287-290.
145. Carson WE, Giri JG, Lindermann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri C: Interleukin (IL-15) is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395.